title: Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.
abstract: In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400mg versus imatinib+cytarabine versus imatinib+interferon (IFN) versus imatinib-600mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib+IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN.
authors.affiliation: Service d'Hématologie Clinique, Hôpital Archet 1, Nice, France; Institut de Biologie Valrose (iBV), UMR CNRS 7277-UMR INSERM 1091, Nice, France. Electronic address: legros@unice.fr.
authors.forename: L
authors.initials: L
authors.lastname: Legros
authors.affiliation: Inserm CIC 0802, CHU de Poitiers, France.
authors.forename: J
authors.initials: J
authors.lastname: Guilhot
authors.affiliation: Institut de Biologie Valrose (iBV), UMR CNRS 7277-UMR INSERM 1091, Nice, France.
authors.forename: S
authors.initials: S
authors.lastname: Huault
authors.affiliation: Laboratoire d'Hématologie et Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux Université Bordeaux Ségalen, INSERM 1035, institut Bergonié, Bordeaux, France.
authors.forename: F X
authors.initials: FX
authors.lastname: Mahon
authors.affiliation: Laboratoire d'hématologie, CHU de Lille, and Inserm U837, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
authors.affiliation: Inserm CIC 0802, CHU de Poitiers, France.
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.affiliation: Institut de Biologie Valrose (iBV), UMR CNRS 7277-UMR INSERM 1091, Nice, France.
authors.forename: A O
authors.initials: AO
authors.lastname: Hueber
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007372:Interferons / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D042461:Vascular Endothelial Growth Factor A; D000068877:Imatinib Mesylate; D007372:Interferons
keywords: Angiogenesis; Chronic myeloid leukemia (CML); Imatinib; Interferon-alpha; Vascular Endothelial Growth Factor (VEGF)